BioMarin Incurs Loss in Q4, Misses Estimates, Gives ’16 View
BioMarin Pharmaceutical Inc. BMRN reported a loss of 58 cents per share in the fourth quarter of 20Array5 (including stock-based compensation expense), wider than the year-ago loss of 29 cents. The Zacks Consensus Estimate was earnings of $Array.03 per share […]